Previously approved for IV infusion.
FDA approved the first and only ready-to-use insulin for IV infusion in hospitals and acute care settings.
FDA recalls insulin pumps due to cybersecurity miscommunication.
While pharmacy benefit managers were grilled about insulin prices at Congressional hearings last week, some PBMs, insurers and pharma makers are already lowering insulin costs.
FDA fast-tracks biosimiliar insulin products to elevate competition.
To stave off competition from other generic makers and appease Congress, Eli Lilly is introducing a generic version of its insulin lispro injection (Humalog).